Catherine E. Rowland

Catherine E. Rowland

Auto-generated profile, based on publicly available information

Catherine E. Rowland

Bicycle Tx Ltd, Blocks A&B, Portway Building, Granta Park, Great Abington, Cambridge, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Current Opinion in Structural Biology
Verified
Journal Article
Open access
CRCatherine E. Rowland
Catherine E. Rowland
GBGustavo Arruda Bezerra
Gustavo Arruda Bezerra
MSMichael J. Skynner
Michael J. Skynner
Macrocyclic peptides are a promising chemotype for drug discovery, given their attractive properties of proteolytic stability, bioavailability and the ability to inhibit protein-protein interactions. Approaches to the generation of macrocyclic peptides include optimisation of hits from library screening; de novo design from known ligands and antibody paratopes or protein-protein interactions; constraint of linear peptides to afford beneficial properties of macrocycles; and novel approaches to cyclisation. We describe the recent literature and exemplify these approaches in the design of peptide macrocycles, and the benefits of incorporating computational and structure-guided approaches into compound design and optimisation. The benefits of the use of structural biology as a component part of phage display campaigns are further exemplified by reference to the optimisation of Bicycle® molecules.

28 May 2025 in Communications Biology
Verified
Journal Article
Open access
PDF file
CRCatherine E. Rowland
Catherine E. Rowland
HNHector Newman
Hector Newman
TMTazmin T. Martin
Tazmin T. Martin
RDRachel Dods
Rachel Dods
NBNikolaos Bournakas
Nikolaos Bournakas
MDMichael J. Dawson
Michael J. Dawson
Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of bicyclic peptide (Bicycle®) inhibitors of E. coli PBP3 (EcPBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent, to our knowledge, a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors. This work demonstrates an approach to rapidly find binders to antimicrobial targets, combined with an entry mechanism to provide access to the Gram negative cell.

6 October 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SAShenaz Allyjaun
Shenaz Allyjaun
EDEmily Dunbar
Emily Dunbar
SHSteven W. Hardwick
Steven W. Hardwick
SNSarah Newell
Sarah Newell
FHFinn Holding
Finn Holding
HNHector Newman
Hector Newman
The lipopolysaccharide (LPS) transport (Lpt) system in Gram-negative bacteria maintains the integrity of the asymmetric bacterial outer membrane (OM). LPS biogenesis systems are essential in most Gram-negative bacteria, with LptDE responsible for the delivery of LPS to the outer leaflet of the OM. As an externally accessible, essential protein, LptDE offers a promising target for inhibitor development without the need for cellular penetration. However, there are no direct inhibitors of E. coli LptDE, and drug discovery is made challenging since it is a membrane target without a conventional active site. Here, the bicycle phage display platform was used in combination with cryogenic-electron microscopy (cryo-EM) and surface plasmon resonance to identify and map bicyclic peptide binders to Shigella flexneri LptDE (SfLptDE). Four distinct epitopes with unique bicycle molecule binding motifs were identified across the SfLptD β-barrel. This method represents a streamlined workflow for the identification and prioritization of hit molecules against LptDE.

21 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CRCatherine E. Rowland
Catherine E. Rowland
HNHector Newman
Hector Newman
TMTazmin T. Martin
Tazmin T. Martin
RDRachel Dods
Rachel Dods
NBNikolaos Bournakas
Nikolaos Bournakas
MDMichael J. Dawson
Michael J. Dawson
Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of β-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of novel, bicyclic peptide (Bicycle ® ) inhibitors of E. coli PBP3 ( Ec PBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent a novel non-β-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors.

10 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJonathan R. Whiteside
Jonathan R. Whiteside
NLNick Lewis
Nick Lewis
LDLaura Díaz-Sáez
Laura Díaz-Sáez
HNHector Newman
Hector Newman
SNSarah Newell
Sarah Newell
CRCatherine E. Rowland
Catherine E. Rowland
α-Hemolysin (Ahly) is a major Staphylococcus aureus virulence determinant implicated in tissue injury and immune dysregulation; antibody inhibitors have reached clinical trials but alternatives with improved ease of manufacture and tissue penetration are desirable. Here we demonstrate that phage-derived bicyclic peptides can serve as compact, chemically tractable Ahly neutralisers. Using TATB-scaffolded M13 phage libraries we identified WNP-motif containing bicyclic binders, with a lead hit of Peptide 14 (K D = 1792nM) and progressed the lead by iterative affinity maturation to Peptide 20 (K D = 609 nM) and by incorporation of strategically chosen non-canonical amino acids to yield Peptide 88 (KD = 96 nM). A 2.2 Å co-crystal structure with AhlyH35A locates the binding footprint on the rim domain and explains the critical role of the WNP motif in target engagement. Functional assays show that the Peptide 88 blocks Ahly mediated hemolysis, inhibits Ahly driven ADAM10 activation, and elucidate its inhibitory mechanism of preventing Ahly binding to human A549 epithelial cells. Peptide 88 protects A549 cells from recombinant toxin and attenuates cytotoxicity in S. aureus co-culture experiments, whilst showing no toxicity to A549 cells. Bicyclic peptides thus represent a new and promising anti-virulence modality: small, synthetically accessible molecules that mimic antibody recognition, with therapeutic potential against S. aureus infections.